Serum sLOX-1 levels are elevated in patients with non-alcoholic fatty liver disease (NAFLD) and correlate positively with the NAFLD activity score [25], reflecting an association with inflammation rather than fibrosis stages [25]. Here, OLR1 is linked to metabolic dysfunction-associated steatotic liver disease.